Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction
摘要:
Starting from quinuclidinyl oxime 1 identified by preliminary screening, a series of azacycles-containing oxime derivatives was synthesized. Their mPTP blocking activities were evaluated by a JC-1 assay, measuring the change of mitochondrial membrane potential. The inhibitory activity of nine compounds against amyloid beta-induced mPTP opening was comparable or even superior to that of piracetam. Among them, 12d effectively maintained mitochondrial function and cell viabilities on the ATP assay, the MTT assay, and the ROS assay. In addition, it exhibited favorable in vitro stability and pharmacokinetic characteristics, which hold a promise for further development of AD therapeutics. (C) 2012 Elsevier Masson SAS. All rights reserved.
Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction
摘要:
Starting from quinuclidinyl oxime 1 identified by preliminary screening, a series of azacycles-containing oxime derivatives was synthesized. Their mPTP blocking activities were evaluated by a JC-1 assay, measuring the change of mitochondrial membrane potential. The inhibitory activity of nine compounds against amyloid beta-induced mPTP opening was comparable or even superior to that of piracetam. Among them, 12d effectively maintained mitochondrial function and cell viabilities on the ATP assay, the MTT assay, and the ROS assay. In addition, it exhibited favorable in vitro stability and pharmacokinetic characteristics, which hold a promise for further development of AD therapeutics. (C) 2012 Elsevier Masson SAS. All rights reserved.
[EN] AZACYCLIC AND AZABICYCLIC HYDROXYLAMINES AS MUSCARINIC RECEPTOR AGONISTS<br/>[FR] ALKYLIDENE HYDROXYLAMINES AZACYCLIQUES ET AZABICYLIQUES UTILES COMME AGONISTES DES RECEPTEURS A LA MUSCARINE
申请人:BOEHRINGER INGELHEIM ITALIA S.P.A.
公开号:WO1994000448A1
公开(公告)日:1994-01-06
(EN) Pharmacologically active azacyclic and azabicyclic alkyliden hydroxylamines as cholinergic agents, useful in the treatment of neurological and mental diseases of formula (I), wherein A, n, R1 and R2 have the meanings specified in the description, a process for their preparation and pharmaceutical compositions containing them, are disclosed.(FR) L'invention concerne des alkylidène hydroxylamines azacycliques et azabicyliques de formule (I), utiles comme agents cholinergiques pour le traitement de troubles neurologiques et mentaux. Dans ladite formule, A, n, R1, et R2 ont la signification spécifiée dans la description. On décrit également un procédé de préparation de ces composés et des compositions pharmaceutiques les contenant.
Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction
作者:Young Seub Kim、Sun hwa Jung、Beoung-Geon Park、Min Kyung Ko、Hyun-Seo Jang、Kihang Choi、Ja-Hyun Baik、Jiyoun Lee、Jae Kyun Lee、Ae Nim Pae、Yong Seo Cho、Sun-Joon Min
DOI:10.1016/j.ejmech.2012.12.033
日期:2013.4
Starting from quinuclidinyl oxime 1 identified by preliminary screening, a series of azacycles-containing oxime derivatives was synthesized. Their mPTP blocking activities were evaluated by a JC-1 assay, measuring the change of mitochondrial membrane potential. The inhibitory activity of nine compounds against amyloid beta-induced mPTP opening was comparable or even superior to that of piracetam. Among them, 12d effectively maintained mitochondrial function and cell viabilities on the ATP assay, the MTT assay, and the ROS assay. In addition, it exhibited favorable in vitro stability and pharmacokinetic characteristics, which hold a promise for further development of AD therapeutics. (C) 2012 Elsevier Masson SAS. All rights reserved.